查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1751200

感染疾病体外诊断市场规模、份额、趋势分析报告：按产品、技术、应用、测试地点、地区、细分市场预测，2025-2030 年

Infectious Disease In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Technology, By Application, By Test Location, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10个工作天内

价格

感染疾病体外诊断市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球感染疾病体外诊断市场规模预计到2030年将达到280.5亿美元，2025年至2030年的复合年增长率为2.54%。

预计未来几年，结核病和新冠肺炎 (COVID-19) 等感染疾病的盛行率上升，以及技术的进步，将推动产品需求成长。多重抗药性感染疾病的增多，强化了早期诊断感染疾病的必要性。例如，根据 2021 年《微生物抗药性期刊》的报告，重症 SARS-CoV-2 患者中多重抗药性感染疾病的盛行率为 14% 至 50%。

诊断前和抗生素治疗的延误进一步加剧了抗药性细菌的传播，为产业成长创造了有利机会。该行业正在推出大量产品以满足消费者需求。例如，2022年5月，BD公司在美国推出了一款感染疾病自动化诊断平台。该系统可加载1700个检体，无需检体分拣，从而减少了错误。各竞争对手的产品定价策略性地加剧了竞争公司之间的竞争。

然而，当消费者由于敏感度和信念的差异而必须在即时检测和实验室检测之间做出选择时，购买行为的复杂性会显着增加。该行业呈现寡占格局，罗氏、阿莱尔、生物梅里埃和 BD 等公司占据了大部分市场份额。全球产业对价格敏感，在生产经济高效的产品方面，各公司之间竞争激烈。由于预计将推出新型生物标记套件，预计预测期内竞争对手之间的竞争将会加剧。竞争对手正在采取产品发布和宣传计划等关键策略，以抢占更高的市场占有率。

感染疾病体外诊断市场报告重点

  • 试剂产品部门在 2024 年占据了最大的收益占有率，因为其在测试中的使用量很大。
  • 从应用角度来看，由于在遏制病毒传播的检测方面投入了大量资金，COVID-19 领域在 2024 年占据了行业主导地位。
  • 根据检测地点，2024 年中央实验室部分占据主导地位，份额为 48.06%。这是由于实验室测试的准确性更高，与即时检测和家庭测试相比更可靠，使这些测试比其他两个部分更具竞争优势。
  • 由于良好的法律规范、对预防和早期检测的重视以及新型诊断药物的高采用率，北美在 2024 年占据了全球产业的主导地位。

目录

第一章调查方法与范围

第二章执行摘要

第三章感染疾病体外诊断市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 感染疾病体外诊断市场分析工具
    • 波特分析
    • PESTEL分析

第四章感染疾病体外诊断市场：按产品分類的估计和趋势分析

  • 细分仪表板
  • 感染疾病体外诊断市场：2024 年及 2030 年产品变化分析
  • 装置
    • MRSA
    • 链球菌
    • 困难梭状芽孢桿菌
    • VRE
    • CRE
    • 呼吸道病毒
    • 念珠菌
    • 结核病和抗药性结核病
    • 胃肠道检查
    • 披衣菌感染
    • 淋病
    • HPV
    • HIV
    • C型肝炎
    • B型肝炎
    • COVID-19
    • 其他感染疾病
  • 试剂
    • MRSA
    • 链球菌
    • 困难梭状芽孢桿菌
    • VRE
    • CRE
    • 呼吸道病毒
    • 念珠菌
    • 结核病和抗药性结核病
    • 胃肠道检查
    • 披衣菌感染
    • 淋病
    • HPV
    • HIV
    • C型肝炎
    • B型肝炎
    • COVID-19
    • 其他感染疾病
  • 软体
    • MRSA
    • 链球菌
    • 困难梭状芽孢桿菌
    • VRE
    • CRE
    • 呼吸道病毒
    • 念珠菌
    • 结核病和抗药性结核病
    • 胃肠道检查
    • 披衣菌感染
    • 淋病
    • HPV
    • HIV
    • C型肝炎
    • B型肝炎
    • COVID-19
    • 其他感染疾病

第五章感染疾病体外诊断市场：依技术分類的估计与趋势分析

  • 细分仪表板
  • 感染疾病体外诊断市场：2024 年和 2030 年技术趋势分析
  • 免疫检测
  • 分子诊断
    • 聚合酵素链锁反应（PCR）
    • 原位杂交
    • 恒温核酸增幅技术（INAAT）
    • 晶片和微阵列
    • 定序和NGS
    • 转录媒介增幅
  • 微生物学
  • 其他的

第六章感染疾病体外诊断市场：按应用的估计和趋势分析

  • 细分仪表板
  • 感染疾病体外诊断市场：2024 年和 2030 年应用趋势分析
  • MRSA
  • 链球菌
  • 困难梭状芽孢桿菌
  • VRE
  • CRE
  • 呼吸道病毒
  • 念珠菌
  • 结核病和抗药性结核病
  • 胃肠道检查
  • 披衣菌感染
  • 淋病
  • HPV
  • HIV
  • C型肝炎
  • B型肝炎
  • COVID-19
  • 其他感染疾病
    • 2018-2019 年其他市场收益估计与预测

第七章感染疾病体外诊断市场：按测试地点的估计和趋势分析

  • 细分仪表板
  • 感染疾病体外诊断市场：2024年及2030年检验地点变化分析
  • 照护现场
  • 中央研究院
  • 其他的

第八章感染疾病体外诊断市场：区域估计与趋势分析

  • 2024 年及 2030 年感染疾病体外诊断市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 丹麦
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第九章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司市场占有率分析
  • 公司热图分析
  • 战略地图
    • 扩张
    • 合併与收购
    • 伙伴关係和合作
    • 新产品发布
    • 研究与开发
  • 公司简介
    • QIAGEN
    • BD
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc.（Gen Probe）
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.
Product Code: 978-1-68038-716-2

Infectious Disease In Vitro Diagnostics Market Growth & Trends:

The global infectious disease in vitro diagnostics market size is estimated to reach USD 28.05 billion by 2030, registering a CAGR of 2.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases, such as tuberculosis & COVID-19, and technological advancements are projected to drive the product demand in the coming years. The rising prevalence of multi-drug resistant infections is enhancing the early diagnosis of infectious diseases. For instance, MDR infections are highly common in ICU patients, as per the Microbial Drug Resistance Journal in 2021, the prevalence of MDR infections in critically ill SARS-CoV-2 patients ranged between14% and 50%.

The delay in diagnosis and treatment with antibiotics before infection diagnosis is further escalating the prevalence of drug resistant-bacteria, creating a lucrative opportunity for industry growth. The industry is witnessing a significant number of product launches to meet the demands of consumers. For instance, in May 2022, BD introduced its automated diagnostic platform for infectious diseases in the U.S. The system allows the loading of 1700 specimens and the need for specimen sorting is also eliminated, thereby, reducing errors. Products offered by various competitors have been strategically priced to increase competitive rivalry.

However, complexity in buying behavior increases prominently when consumers have to choose between PoC and lab-based tests owing to differences in sensitivity and beliefs. The industry is oligopolistic with companies, such as Hoffmann-La Roche Ltd., Alere, bioMerieux, and BD, holding the majority of the share collectively. The global industry is price-sensitive, creating rigorous competition among players in terms of manufacturing cost-effective and efficient products. Competitive rivalry is estimated to increase during the forecast period owing to the expected launch of novel biomarker kits. Competitors are adopting key strategies, such as product launches and organizing awareness programs, to gain higher market shares.

Infectious Disease In Vitro Diagnostics Market Report Highlights:

  • The reagents product segment held the largest revenue share in 2024, owing to its high-volume usage in testing.
  • By application, the COVID-19 segment dominated the industry in 2024, due to the high expenditure on testing, to reduce the spread of the virus
  • Based on test location, the central laboratories segment dominated in 2024 with a share of 48.06%, due to the higher accuracy of laboratory-based tests, which makes them more reliable as compared to PoC and home tests, giving these tests a competitive edge over the other two segments
  • North America dominated the global industry in 2024, due to its favorable regulatory framework, focus on preventive & early testing, and the higher adoption rate of novel diagnostics in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. Test Location
  • 1.3. Regional Scope
  • 1.4. Estimates and Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
  • 1.7. Details of primary research
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
      • 1.9.1.1. Approach 1: Commodity flow approach
    • 1.9.2. Volume price analysis (Model 2)
      • 1.9.2.1. Approach 2: Volume price analysis
  • 1.10. Research Scope and Assumptions
    • 1.10.1. List of Secondary Sources
    • 1.10.2. List of Primary Sources
    • 1.10.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Infectious Disease In Vitro Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Growing geriatric population
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. High demand for PoC facilities
      • 3.2.1.4. Increasing prevalence of infectious diseases
      • 3.2.1.5. External funding for R&D activities
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High prices of IVD tests
  • 3.3. Infectious Disease In Vitro Diagnostics Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Legal landscape

Chapter 4. Infectious Disease In Vitro Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Infectious Disease In Vitro Diagnostics Market: Product Movement Analysis, USD Billion, 2024 & 2030
  • 4.3. Instruments
    • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.2. MRSA
      • 4.3.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.3. Streptococcus
      • 4.3.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.4. Clostridium Difficile
      • 4.3.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.5. VRE
      • 4.3.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.6. CRE
      • 4.3.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.7. Respiratory Virus
      • 4.3.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.8. Candida
      • 4.3.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.9. TB and Drug-resistant TB
      • 4.3.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.10. Gastro-intestinal Panel Testing
      • 4.3.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.11. Chlamydia
      • 4.3.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.12. Gonorrhea
      • 4.3.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.13. HPV
      • 4.3.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.14. HIV
      • 4.3.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.15. Hepatitis C
      • 4.3.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.16. Hepatitis B
      • 4.3.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.17. COVID-19
      • 4.3.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.18. Other Infectious Diseases
      • 4.3.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Reagents
    • 4.4.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2. MRSA
      • 4.4.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.3. Streptococcus
      • 4.4.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.4. Clostridium Difficile
      • 4.4.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.5. VRE
      • 4.4.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.6. CRE
      • 4.4.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.7. Respiratory Virus
      • 4.4.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.8. Candida
      • 4.4.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.9. TB and Drug-resistant TB
      • 4.4.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.10. Gastro-intestinal Panel Testing
      • 4.4.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.11. Chlamydia
      • 4.4.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.12. Gonorrhea
      • 4.4.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.13. HPV
      • 4.4.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.14. HIV
      • 4.4.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.15. Hepatitis C
      • 4.4.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.16. Hepatitis B
      • 4.4.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.17. COVID-19
      • 4.4.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.18. Other Infectious Diseases
      • 4.4.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Software
    • 4.5.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2. MRSA
      • 4.5.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.3. Streptococcus
      • 4.5.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.4. Clostridium Difficile
      • 4.5.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.5. VRE
      • 4.5.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.6. CRE
      • 4.5.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.7. Respiratory Virus
      • 4.5.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.8. Candida
      • 4.5.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.9. TB and Drug-resistant TB
      • 4.5.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.10. Gastro-intestinal Panel Testing
      • 4.5.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.11. Chlamydia
      • 4.5.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.12. Gonorrhea
      • 4.5.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.13. HPV
      • 4.5.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.14. HIV
      • 4.5.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.15. Hepatitis C
      • 4.5.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.16. Hepatitis B
      • 4.5.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.17. COVID-19
      • 4.5.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.18. Other Infectious Diseases
      • 4.5.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Infectious Disease In Vitro Diagnostics Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Infectious Disease In Vitro Diagnostics Market: Technology Movement Analysis, USD Billion, 2024 & 2030
  • 5.3. Immunoassay
    • 5.3.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Molecular Diagnostics
    • 5.4.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.2. Polymerase Chain Reaction (PCR)
      • 5.4.2.1. Polymerase Chain Reaction (PCR) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. In Situ Hybridization
      • 5.4.3.1. In Situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
      • 5.4.4.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.5. Chips and Microarrays
      • 5.4.5.1. Chips and Microarrays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.6. Sequencing & NGS
      • 5.4.6.1. Sequencing & NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.7. Transcription Mediated Amplification
      • 5.4.7.1. Transcription Mediated Amplification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Microbiology
    • 5.5.1. Microbiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Infectious Disease In Vitro Diagnostics Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Infectious Disease In Vitro Diagnostics Market: Application Movement Analysis, USD Billion, 2024 & 2030
  • 6.3. MRSA
    • 6.3.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Streptococcus
    • 6.4.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Clostridium difficile
    • 6.5.1. Clostridium difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. VRE
    • 6.6.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. CRE
    • 6.7.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.8. Respiratory Virus
    • 6.8.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.9. Candida
    • 6.9.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.10. TB and drug-resistant TB
    • 6.10.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.11. Gastro-intestinal panel testing
    • 6.11.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.12. Chlamydia
    • 6.12.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.13. Gonorrhea
    • 6.13.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.14. HPV
    • 6.14.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.15. HIV
    • 6.15.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.16. Hepatitis C
    • 6.16.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.17. Hepatitis B
    • 6.17.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.18. COVID-19
    • 6.18.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.19. Other Infectious Diseases
    • 6.19.1. Others Market Revenue Estimates and Forecasts, 2018 -

Chapter 7. Infectious Disease In Vitro Diagnostics Market: Test Location Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Infectious Disease In Vitro Diagnostics Market: Test Location Movement Analysis, USD Billion, 2024 & 2030
  • 7.3. Point of Care
    • 7.3.1. Point of Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Central Laboratories
    • 7.4.1. Central Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Infectious Disease In Vitro Diagnostics Market: Regional Estimates & Trend Analysis

  • 8.1. Infectious Disease In Vitro Diagnostics Market Share, By Region, 2024 & 2030, USD Billion
  • 8.2. North America
    • 8.2.1. North America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.2.3. Competitive Insights
      • 8.2.2.4. U.S. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.3.3. Competitive Insights
      • 8.2.3.4. Canada Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.4.3. Competitive Insights
      • 8.2.4.4. Mexico Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.2. U.K.
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.2.3. Competitive Insights
      • 8.3.2.4. U.K. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.3.3. Competitive Insights
      • 8.3.3.4. Germany Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.4.3. Competitive Insights
      • 8.3.4.4. France Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.5.3. Competitive Insights
      • 8.3.5.4. Italy Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.6.3. Competitive Insights
      • 8.3.6.4. Spain Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.7. Sweden
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.7.3. Competitive Insights
      • 8.3.7.4. Sweden Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.8.3. Competitive Insights
      • 8.3.8.4. Denmark Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.9.3. Competitive Insights
      • 8.3.9.4. Norway Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.2. China
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. China Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Japan Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. India Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.5.3. Competitive Insights
      • 8.4.5.4. South Korea Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.6.3. Competitive Insights
      • 8.4.6.4. Australia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.7.3. Competitive Insights
      • 8.4.7.4. Thailand Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. Brazil Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Argentina Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Saudi Arabia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. UAE
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. UAE Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. South Africa
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. South Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. Kuwait Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Market Share Analysis
  • 9.4. Company Heat Map Analysis
  • 9.5. Strategy Mapping
    • 9.5.1. Expansion
    • 9.5.2. Mergers & Acquisition
    • 9.5.3. Partnerships & Collaborations
    • 9.5.4. New Product Launches
    • 9.5.5. Research And Development
  • 9.6. Company Profiles
    • 9.6.1. QIAGEN
      • 9.6.1.1. Participant's Overview
      • 9.6.1.2. Financial Performance
      • 9.6.1.3. Product Benchmarking
      • 9.6.1.4. Recent Developments
    • 9.6.2. BD
      • 9.6.2.1. Participant's Overview
      • 9.6.2.2. Financial Performance
      • 9.6.2.3. Product Benchmarking
      • 9.6.2.4. Recent Developments
    • 9.6.3. bioMerieux SA
      • 9.6.3.1. Participant's Overview
      • 9.6.3.2. Financial Performance
      • 9.6.3.3. Product Benchmarking
      • 9.6.3.4. Recent Developments
    • 9.6.4. F. Hoffmann-La Roche, Ltd.
      • 9.6.4.1. Participant's Overview
      • 9.6.4.2. Financial Performance
      • 9.6.4.3. Product Benchmarking
      • 9.6.4.4. Recent Developments
    • 9.6.5. Hologic, Inc. (Gen Probe)
      • 9.6.5.1. Participant's Overview
      • 9.6.5.2. Financial Performance
      • 9.6.5.3. Product Benchmarking
      • 9.6.5.4. Recent Developments
    • 9.6.6. Abbott
      • 9.6.6.1. Participant's Overview
      • 9.6.6.2. Financial Performance
      • 9.6.6.3. Product Benchmarking
      • 9.6.6.4. Recent Developments
    • 9.6.7. Quidel Corporation
      • 9.6.7.1. Participant's Overview
      • 9.6.7.2. Financial Performance
      • 9.6.7.3. Product Benchmarking
      • 9.6.7.4. Recent Developments
    • 9.6.8. Siemens Healthineers AG
      • 9.6.8.1. Participant's Overview
      • 9.6.8.2. Financial Performance
      • 9.6.8.3. Product Benchmarking
      • 9.6.8.4. Recent Developments
    • 9.6.9. Bio-Rad Laboratories, Inc.
      • 9.6.9.1. Participant's Overview
      • 9.6.9.2. Financial Performance
      • 9.6.9.3. Product Benchmarking
      • 9.6.9.4. Recent Developments
    • 9.6.10. Danaher
      • 9.6.10.1. Participant's Overview
      • 9.6.10.2. Financial Performance
      • 9.6.10.3. Product Benchmarking
      • 9.6.10.4. Recent Developments
    • 9.6.11. OraSure Technologies, Inc.
      • 9.6.11.1. Participant's Overview
      • 9.6.11.2. Financial Performance
      • 9.6.11.3. Product Benchmarking
      • 9.6.11.4. Recent Developments

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global IVD Infectious Diseases Market, By Region, 2018 - 2030 (USD Billion)
  • Table 5 Global IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 6 Global IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 7 Global IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 8 Global IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 9 North America IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 10 North America IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 11 North America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 12 North America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 13 North America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 14 U.S. IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 15 U.S. IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 16 U.S. IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 17 U.S. IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 18 Canada IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 19 Canada IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 20 Canada IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 21 Canada IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 22 Mexico IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 23 Mexico IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 24 Mexico IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 25 Mexico IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 26 Europe IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 27 Europe IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 28 Europe IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 29 Europe IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 30 Europe IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 31 U.K. IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 32 U.K. IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 33 U.K. IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 34 U.K. IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 35 Germany IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 36 Germany America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 37 Germany America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 38 Germany America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 39 France IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 40 France IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 41 France IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 42 France IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 43 Spain IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 44 Spain IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 45 Spain IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 46 Spain IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 47 Italy IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 48 Italy IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 49 Italy IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 50 Italy IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 51 Denmark IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 52 Denmark IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 53 Denmark IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 54 Denmark IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 55 Sweden IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 56 Sweden IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 57 Sweden IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 58 Sweden IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 59 Norway IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 60 Norway IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 61 Norway IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 62 Norway IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 63 Asia Pacific IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 64 Asia Pacific IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 65 Asia Pacific IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 66 Asia Pacific IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 67 Asia Pacific IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 68 China IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 69 China IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 70 China IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 71 China IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 72 Japan IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 73 Japan IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 74 Japan IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 75 Japan IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 76 India IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 77 India IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 78 India IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 79 India IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 80 South Korea IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 81 South Korea IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 82 South Korea IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 83 South Korea IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 84 Thailand IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 85 Thailand IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 86 Thailand IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 87 Thailand IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 88 Australia IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 89 Australia IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 90 Australia IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 91 Australia IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 92 Latin America IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 93 Latin America IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 94 Latin America IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 95 Latin America IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 96 Latin America IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 97 Brazil IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 98 Brazil IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 99 Brazil IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 100 Brazil IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 101 Argentina IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 102 Argentina IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 103 Argentina IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 104 Argentina IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 105 MEA IVD Infectious Diseases Market, By Country, 2018 - 2030 (USD Billion)
  • Table 106 MEA IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 107 MEA IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 108 MEA IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 109 MEA IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 110 South Africa IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 111 South Africa IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 112 South Africa IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 113 South Africa IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 114 UAE IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 115 UAE IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 116 UAE IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 117 UAE IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 118 Saudi Arabia IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 119 Saudi Arabia IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 120 Saudi Arabia IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 121 Saudi Arabia IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait IVD Infectious Diseases Market, By Product, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait IVD Infectious Diseases Market, By Technology, 2018 - 2030 (USD Billion)
  • Table 124 Kuwait IVD Infectious Diseases Market, By Application, 2018 - 2030 (USD Billion)
  • Table 125 Kuwait IVD Infectious Diseases Market, By Test Location, 2018 - 2030 (USD Billion)

List of Figures

  • Fig.1 IVD infectious diseases market segmentation
  • Fig.2 Market research process
  • Fig.3 Information procurement
  • Fig.4 Primary research pattern
  • Fig.5 Primary interviews in North America
  • Fig.6 Primary interviews in Europe
  • Fig.7 Primary interviews in Asia Pacific
  • Fig.8 Primary interviews in Middle East and Africa
  • Fig.9 Market research approaches
  • Fig.10 Value-chain-based sizing & forecasting
  • Fig.11 QFD modeling for market share assessment
  • Fig.12 Market formulation & validation
  • Fig.13 IVD infectious disease market snapshot
  • Fig.14 Segment Insights
  • Fig.15 Strategy framework
  • Fig.16 Penetration & growth prospect mapping
  • Fig.17 Consumer behavior analysis
  • Fig.18 Factors influencing North America IVD infectious diseases market (%)
  • Fig.19 Factors influencing Europe IVD infectious diseases market (%)
  • Fig.20 Factors influencing Asia Pacific IVD infectious diseases market (%)
  • Fig.21 Factors influencing Latin America IVD infectious diseases market (%)
  • Fig.22 Factors influencing Middle East and Africa IVD infectious diseases market (%)
  • Fig.23 Market driver relevance analysis (Current & future impact)
  • Fig.24 Global population growth, by age-group, 2012 - 2022 (Million)
  • Fig.25 Global percentage of population, by age group, 2000 and 2050
  • Fig.26 General trend of CLIA-waived tests
  • Fig.27 Market restraint relevance analysis (Current & future impact)
  • Fig.28 Porter's five forces analysis
  • Fig.29 PESTLE analysis
  • Fig.30 Strategy mapping
  • Fig.31 IVD infectious diseases market: Product movement analysis
  • Fig.32 Product segment dashboard
  • Fig.33 IVD infectious diseases market product outlook: Key takeaways
  • Fig.34 Instruments market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.35 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.36 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.37 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.38 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.39 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.40 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.41 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.42 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.43 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.44 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.45 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.46 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.47 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.48 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.49 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.50 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.51 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.52 Reagents market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.53 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.54 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.55 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.56 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.57 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.58 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.59 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.60 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.61 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.62 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.63 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.64 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.65 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.66 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.67 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.68 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.69 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.70 Software market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.71 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.72 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.73 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.74 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.75 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.76 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.77 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.78 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.79 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.80 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.81 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.82 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.83 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.84 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.85 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.86 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.87 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.88 IVD infectious diseases market: Technology movement analysis
  • Fig.89 Technology segment dashboard
  • Fig.90 IVD infectious diseases market technology outlook: Key takeaways
  • Fig.91 Immunoassay market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.92 Molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.93 PCR market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.94 In Situ Hybridization market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.95 INAAT market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.96 Chips and microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.97 Sequencing & NGS market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.98 TMA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.99 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.100 Microbiology market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.101 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.102 IVD infectious diseases market: Technology movement analysis
  • Fig.103 Application segment dashboard
  • Fig.104 IVD infectious diseases market technology outlook: Key takeaways
  • Fig.105 MRSA market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.106 Streptococcus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.107 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.108 VRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.109 CRE market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.110 Respiratory virus market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.111 Candida market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.112 TB & drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.113 GI panel testing market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.114 Chlamydia market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.115 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.116 HPV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.117 HIV market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.118 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.119 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.120 COVID-19 market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.121 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.122 IVD infectious diseases market: Test location movement analysis
  • Fig.123 Test location segment dashboard
  • Fig.124 IVD infectious diseases market test location outlook: Key takeaways
  • Fig.125 Point of Care market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.126 Central laboratories market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.127 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.128 Regional outlook, 2023 & 2030
  • Fig.129 Regional market dashboard
  • Fig.130 Regional marketplace: Key takeaways
  • Fig.131 North America market share and leading players, 2023
  • Fig.132 Europe market share and leading players, 2023
  • Fig.133 Asia Pacific market share and leading players, 2023
  • Fig.134 Latin America market share and leading players, 2023
  • Fig.135 Middle East and Africa market share and leading players, 2023
  • Fig.136 North America, SWOT
  • Fig.137 Europe, SWOT
  • Fig.138 Asia Pacific, SWOT
  • Fig.139 Latin America, SWOT
  • Fig.140 Middle East and Africa, SWOT
  • Fig.141 North America IVD infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig.142 U.S. key country dynamics
  • Fig.143 U.S. IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.144 Canada key country dynamics
  • Fig.145 Canada IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.146 Europe IVD infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig.147 UK key country dynamics
  • Fig.148 UK IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.149 Germany key country dynamics
  • Fig.150 Germany IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.151 Spain key country dynamics
  • Fig.152 Spain IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.153 France key country dynamics
  • Fig.154 France IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.155 Italy key country dynamics
  • Fig.156 Italy IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.157 Denmark key country dynamics
  • Fig.158 Denmark IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.159 Sweden key country dynamics
  • Fig.160 Sweden IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.161 Norway key country dynamics
  • Fig.162 Norway IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.163 Asia Pacific IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.164 Japan key country dynamics
  • Fig.165 Japan IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.166 China key country dynamics
  • Fig.167 China IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.168 India key country dynamics
  • Fig.169 India IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.170 South Korea key country dynamics
  • Fig.171 South Korea IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.172 Australia key country dynamics
  • Fig.173 Australia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.174 Thailand key country dynamics
  • Fig.175 Thailand IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.176 Latin America IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.177 Brazil key country dynamics
  • Fig.178 Brazil IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.179 Mexico key country dynamics
  • Fig.180 Mexico IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.181 Argentina key country dynamics
  • Fig.182 Argentina IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.183 MEA IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.184 South Africa key country dynamics
  • Fig.185 South Africa IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.186 Saudi Arabia key country dynamics
  • Fig.187 Saudi Arabia IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.188 UAE key country dynamics
  • Fig.189 UAE IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.190 Kuwait key country dynamics
  • Fig.191 Kuwait IVD infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig.192 Ansoff Matrix
  • Fig.193 Heat map analysis
  • Fig.194 Company market share analysis,2023
  • Fig.195 Company market position analysis
  • Fig.196 Market differentiators